The originating document has been archived. We cannot confirm the completeness, accuracy, or currency of the content.
Sancuso Dosage
Generic name: granisetron 3.1mg in 24h
Dosage form: transdermal patch
Drug class: 5HT3 receptor antagonists
The recommended dosage is a single transdermal system applied to the upper outer arm a minimum of 24 hours, up to a maximum of 48 hours, before chemotherapy. The transdermal system should be worn at minimum, 24 hours after chemotherapy is finished. The transdermal system can be worn for up to 7 days.
Application and Removal Instructions
- Each transdermal system releases 3.1 mg of granisetron per 24 hours for up to 7 days.
- Each transdermal system is packed in a pouch and should be applied directly after the pouch has been opened.
- Only wear one transdermal system at any time.
- Do not cut the transdermal system.
- Open the pouch and apply the transdermal system to clean, dry, nearly hairless, intact healthy skin on the upper outer arm.
- Do not place Sancuso transdermal system on skin that is red, irritated, or damaged.
- Do not apply a heat pad or heat lamp over or in vicinity of the transdermal system and avoid extended exposure to heat [see Warnings and Precautions (5.4)].
- Cover the application site of the transdermal system with clothing, if there is a risk of exposure to direct natural or artificial sunlight throughout the period of wear and for 10 days following its removal [see Warnings and Precautions (5.5)].
- After the transdermal system is applied, wash hands thoroughly.
- Remove the transdermal system by peeling off gently from the skin.
- Upon removal, fold the transdermal system in half with the sticky side together, and discard in the household trash in a manner that prevents accidental contact or ingestion by children, pets or others.
- Sancuso contains granisetron. Do not use other granisetron-containing products with Sancuso.
More about Sancuso (granisetron)
- Sancuso consumer information
- Check interactions
- Compare alternatives
- Reviews (15)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: 5HT3 receptor antagonists
- Breastfeeding
- En español
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.